The researchers are doing this study to look at changes in Ki67 expression after at least 2 weeks of endocrine therapy in people with ER+/HER2- breast cancer undergoing cancer removal surgery. Participants will receive the endocrine therapy before their surgery. The researchers will look at how changes in Ki67 expression compare between participants who are carriers of the BRCA2 mutation and participants who are noncarriers of the BRCA2 mutation.
Postmenopausal women aged ≥18 years with biopsy-proven stage I-III invasive breast cancer that is ER+/HER2-
Scheduled to undergo upfront surgery
Eligible for genetic testing in accordance with National Comprehensive Cancer Network guidelines(BRCA2 arm only)
History of breast cancer
Receipt of ET for risk reduction in the previous 3 months
Stage IV disease at presentation
Scheduled to undergo neoadjuvant systemic chemotherapy
Single group
blood draw
Other interventionblood draw
assess the change in Ki67
The change in Ki67 expression on immunohistochemical staining from baseline to at least 2 weeks of ET will be assessed.
Click on the lead sponsor to view all of their trials.
